spacer
home > ebr > winter 2018 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

This edition of EBR went to press just as a major breakthrough in the development of a potential treatment for Huntington’s disease was announced by researchers at University College London. Identifying, isolating and then being able to block synthesis of the defective, toxic proteins responsible for disease pathology has taken decades to accomplish, and a number of articles in our current issue resonate with aspects of this journey from gene to treatment. Although the exact neurological role of the Huntingtin gene product is not yet known, it is a complex, highly polymorphic protein and has the ability to identify even subtle changes from a core range of sequences, and structures of biological relevance through functional approaches such as microarrays could become increasingly valuable tools in disease research. The faulty Huntingtin gene responsible for Huntington’s disease was discovered in 1993.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

E Ink and Faubel Unveil the Med Label to Revolutionize the Clinical Trial Supply Chain

E Ink® Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and Faubel & Co. Nachf. GmbH, a proven supplier to the pharmaceutical and chemical industry, announced the availability of the Faubel-Med® Label, a smart label for investigational medicinal products. The Med Label features E Ink’s low-voltage film technology, bringing display modules and new system designs to pharmaceutical packaging.
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 
Industry Events

Clinical Trial Supply Nordics 2018

19-20 June 2018, Copenhagen, Denmark

Building on last year’s success, our CTS team have conducted extensive research to ensure the 2018 event programme covers all the essentials in clinical supply. In the current climate, every pharma and biotech company are trying to reduce unwanted costs, and enhance operational efficiency. To avoid costly setbacks, an innovative and effective strategy needs to be implemented!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement